Evidence map›Paper›PMID 36982817›Full record

ArticleInternational journal of molecular sciences2023

New 4,5-Diarylimidazol-2-ylidene-iodidogold(I) Complexes with High Activity against Esophageal Adenocarcinoma Cells.

Sebastian W Schleser, Hindole Ghosh, Gerald Hörner, Jonathan Seib, Sangita Bhattacharyya, Birgit Weber, Rainer Schobert, Prasad Dandawate, Bernhard Biersack

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. NewInternational journal of molecular sciences · 2026
    Article
  2. Review
  3. NovelCancer drug resistance (Alhambra, Calif.) · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Sebastian W SchleserOrganic Chemistry 1, University of Bayreuth, Universitätsstrasse 30, 95440 Bayreuth, Germany.
Hindole GhoshCancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
Gerald HörnerInorganic Chemistry IV, University of Bayreuth, Universitätsstrasse 30, 95440 Bayreuth, Germany.ORCID 0000-0002-3883-2879
Jonathan SeibOrganic Chemistry 1, University of Bayreuth, Universitätsstrasse 30, 95440 Bayreuth, Germany.
Sangita BhattacharyyaCancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
Birgit WeberInorganic Chemistry IV, University of Bayreuth, Universitätsstrasse 30, 95440 Bayreuth, Germany.ORCID 0000-0002-9861-9447
Rainer SchobertOrganic Chemistry 1, University of Bayreuth, Universitätsstrasse 30, 95440 Bayreuth, Germany.ORCID 0000-0002-8413-4342
Prasad DandawateCancer Biology, University of Kansas Medical Center, 3901 Rainbow Boulevard, Kansas City, KS 66160, USA.
Bernhard BiersackOrganic Chemistry 1, University of Bayreuth, Universitätsstrasse 30, 95440 Bayreuth, Germany.ORCID 0000-0001-7305-346X
University of Bayreuth · DEThe University of Kansas Cancer Center · US

Funding

Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
XRAY CRYSTALLOGRAPHY CORE (JANUARY 1 - JUNE 30, 2005)P20RR016443 · NCRR · UNIVERSITY OF KANSAS MEDICAL CENTER · PI STEPHENS, EDWARD BRICE · 2001 to 2010
$21.3M
Mechanisms mediating resistance to ibrutinib in Non-Hodgkin's lymphomaR01CA201135 · NCI · SEATTLE CHILDREN'S HOSPITAL · PI JAMES, RICHARD GOFF · 2017 to 2021
$2.1M
NCI NIH HHS P30 CA168524NCI NIH HHS R01 CA201135NCRR NIH HHS P20 RR016443
6 · The paper itself

Abstract

Inspired by the vascular-disrupting agent combretastatin A-4 and recently published anticancer active

Indexed as

AdenocarcinomaCoordination ComplexesHeterocyclic CompoundsCell DeathCrystallography, X-RayGoldHumansMethaneMolecular StructureCoordination ComplexesGoldHeterocyclic CompoundsMethaneanticancer agentscarbene ligandsesophageal cancergoldmetal-based drugs

Identifiers

PMID36982817
PMCPMC10052191
OpenAlexW4327730486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.